Enteric Disease Testing Market Growth Backed by Rising Global Disease Burden
The Enteric Disease Testing Market was valued at USD 3.80 billion in 2023 and is projected to reach USD 5.25 billion by 2032, growing at a CAGR of 3.70% from 2024 to 2032. This growth reflects the increasing global burden of bacterial, viral, and parasitic gastrointestinal infections and the urgent need for early, accurate diagnosis. Enteric disease testing plays a critical role in identifying pathogens responsible for conditions such as salmonellosis, norovirus infection, and giardiasis, supporting timely treatment and outbreak control.
Growing public awareness of gastrointestinal health, combined with stricter food and water safety regulations, has accelerated diagnostic adoption across hospitals, diagnostic laboratories, and research institutions. The market is also benefiting from technological advancements such as PCR-based panels, laboratory automation, and AI-enabled diagnostic workflows, which enhance testing accuracy and efficiency.
Get Ahead of Market Shifts: Request Your Sample Report: https://www.snsinsider.com/sample-request/6236
U.S. Market Expansion Supported by Advanced Healthcare Infrastructure
The U.S. Enteric Disease Testing Market was valued at USD 1.0 billion in 2023 and is expected to reach USD 1.38 billion by 2032, registering a CAGR of 3.69% during the forecast period. High disease incidence, strong regulatory oversight, and widespread availability of advanced diagnostic technologies continue to support market expansion in the country. According to the CDC, foodborne illnesses affect nearly 48 million Americans annually, reinforcing the need for rapid and reliable enteric disease testing solutions.
Rising Incidence of Enteric Diseases Drives Diagnostic Demand
The increasing prevalence of enteric diseases caused by pathogens such as Salmonella, Clostridium difficile, Norovirus, Rotavirus, Giardia, and Cryptosporidium remains a key growth driver for the Enteric Disease Testing Market. Frequent foodborne and waterborne outbreaks have compelled governments and public health agencies to strengthen surveillance and early detection programs. The WHO has also highlighted the growing threat of antimicrobial-resistant enteric pathogens, further boosting demand for advanced molecular diagnostics capable of precise pathogen identification.
Leading diagnostic companies have responded by expanding PCR-based and multiplex testing panels that enable faster detection and improved clinical outcomes. Early diagnosis through enteric disease testing not only improves patient management but also reduces healthcare costs by preventing large-scale outbreaks.
Molecular Diagnostics and Laboratory Automation Reshape Testing Landscape
Advancements in molecular diagnostics are transforming the Enteric Disease Testing Market. PCR-based assays, next-generation sequencing, and syndromic gastrointestinal panels offer superior sensitivity and shorter turnaround times compared to conventional culture methods. Regulatory approvals for multiplex molecular panels have increased adoption in hospitals and reference laboratories.
Automation has further optimized diagnostic workflows by minimizing manual errors, increasing throughput, and reducing result turnaround times. AI-based analytics and automated sample preparation systems are making high-volume enteric disease testing more scalable and cost-efficient, especially in regions with high infection rates.
High Cost and Limited Access Restrain Market Penetration
Despite technological progress, high costs associated with advanced molecular tests remain a major restraint in the Enteric Disease Testing Market. PCR and NGS-based assays can range from USD 50 to USD 300 per test, limiting accessibility in low- and middle-income regions. Many laboratories in resource-limited settings lack the infrastructure and trained personnel needed to implement advanced diagnostic platforms, resulting in continued reliance on slower, less sensitive culture-based methods.
These cost and access disparities delay early diagnosis and outbreak control, particularly in regions with a high burden of enteric diseases.
Point-of-Care Testing Creates New Growth Opportunities
The rising demand for rapid, affordable, and decentralized diagnostic solutions presents significant opportunities in the Enteric Disease Testing Market. Point-of-care and home-based testing kits enable quicker detection of gastrointestinal pathogens without the need for centralized laboratories. Rapid immunoassay-based stool tests now deliver results within minutes, supporting timely clinical decisions.
The expansion of telemedicine and online healthcare platforms has further accelerated adoption of at-home enteric disease testing kits, particularly in rural and underserved areas. Government initiatives supporting self-testing and decentralized diagnostics are expected to drive strong growth in this segment through 2030.
Regulatory Variability Challenges Market Expansion
Inconsistent regulatory standards across regions pose challenges for market players. Stringent compliance requirements under the European Union’s IVDR and rigorous FDA approval processes in the U.S. can delay product launches and increase development costs. Conversely, the lack of standardized regulations in some developing regions can lead to quality inconsistencies and limited market penetration. Harmonization of global regulatory frameworks remains essential for accelerating innovation and improving access to enteric disease testing worldwide.
Bacterial Infections Lead Disease-Based Segmentation
Bacterial enteric diseases accounted for approximately 54.31% of the Enteric Disease Testing Market in 2023. High infection rates associated with Salmonella, E. coli, Campylobacter, and Clostridium difficile have driven strong demand for rapid and accurate diagnostics. Rising hospital-acquired infections and stricter food safety regulations have further reinforced the dominance of bacterial testing solutions, particularly multiplex PCR and immunoassay platforms.
Immunoassays Maintain Strong Position by Test Type
Immunoassays held around 46.32% market share in 2023 due to their affordability, ease of use, and quick turnaround time. ELISA and lateral flow assays remain widely used across hospitals, clinical laboratories, and point-of-care settings. Their accessibility in developing regions where molecular diagnostics are limited has significantly supported segment growth.
Hospitals Dominate End-Use Adoption
Hospitals represented 42.11% of the Enteric Disease Testing Market in 2023, driven by high patient volumes and the need for rapid diagnosis of acute gastrointestinal infections and hospital-acquired infections. Advanced laboratory infrastructure and skilled professionals have enabled hospitals to adopt automated molecular and immunoassay-based testing solutions at scale.
Interest in Market Trends: Get Detailed Analysis and Insights with Our Comprehensive Report: https://www.snsinsider.com/reports/enteric-disease-testing-market-6236
North America Leads While Asia Pacific Grows Rapidly
North America dominated the market with a 38.42% share in 2023, supported by advanced healthcare infrastructure, high disease awareness, and strong government initiatives related to food safety and antimicrobial resistance monitoring. Asia Pacific is expected to be the fastest-growing region, registering a CAGR of 4.25%, driven by high disease prevalence, urbanization, expanding healthcare access, and increasing adoption of low-cost rapid diagnostic kits.
Key Players
Abbott Laboratories, Becton Dickinson and Company, Biomerica Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Cepheid, Coris BioConcept, DiaSorin S.p.A., Meridian Bioscience Inc., Quest Diagnostics, Trinity Biotech, Thermo Fisher Scientific, Quansys Biosciences Inc., SGS, Merck, Roche Diagnostics, GenMark Diagnostics, Luminex Corporation, Hologic Inc., Siemens Healthineers
Future Outlook
The Enteric Disease Testing Market is expected to witness steady growth through 2032, supported by rising disease incidence, continuous innovation in molecular diagnostics, and expanding point-of-care testing adoption. Increased investments in laboratory automation, AI-enabled diagnostics, and decentralized testing solutions will further enhance market scalability and accessibility. Emerging economies are likely to present strong growth opportunities as governments strengthen infectious disease surveillance and healthcare infrastructure.
Conclusion
The Enteric Disease Testing Market is evolving as a critical component of global public health management. With rising foodborne and waterborne infections, demand for rapid, accurate, and accessible diagnostics continues to grow. While cost and regulatory challenges persist, advancements in molecular testing, automation, and point-of-care solutions position the market for sustained expansion over the coming decade.
Explore SNS Insider Related Ongoing Coverage on Healthcare Market Insights Domain:
Isothermal Nucleic Acid Amplification Technology Market
Frequently Asked Questions (FAQ)
What is the current valuation of the Enteric Disease Testing Market?
The market was valued at USD 3.80 billion in 2023.
What is the projected market size by 2032?
The Enteric Disease Testing Market is expected to reach USD 5.25 billion by 2032.
What is the growth rate of the Enteric Disease Testing Market?
The market is projected to grow at a CAGR of 3.70% from 2024 to 2032.
Which region dominates the Enteric Disease Testing Market?
North America dominated the market in 2023 with a 38.42% share.
Which test type holds the largest market share?
Immunoassay-based tests held the largest share at 46.32% in 2023.
